Pruritus Therapeutics Market Revenue, Product Launches, Regional Share Analysis & Forecast Till 2028

Comments · 63 Views

The Pruritus Therapeutics Market is estimated to account for over USD 19.98 Billion by 2028 from USD 12.40 Billiion in 2020, registering a CAGR of approximately 6.2% through the forecast period.

The Pruritus Therapeutics Market is experiencing significant growth and is projected to reach a value of over USD 19.98 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.2% throughout the forecast period. This growth can be attributed to the increasing prevalence of skin diseases.

Pruritus, commonly known as itching, is often associated with primary skin disorders such as atopic dermatitis, xerosis, drug eruptions, psoriasis, urticaria, arthropod assaults, dermatitis herpetiformis, and mastocytosis. It manifests as an unpleasant sensation that triggers the urge to scratch or itch. Pruritus is frequently linked to systemic diseases and can range in severity from mild itchiness to a persistent, debilitating condition. Generalized pruritus, based on the underlying causative disease, can be categorized into various types, including cholestatic pruritus, renal pruritus, hematologic pruritus, idiopathic generalized pruritus, endocrine pruritus, and pruritus related to malignancy. Chronic pruritus is commonly observed in pregnant women, with around 18% of all pregnant women experiencing pruritus.

Competitive Landscape:

Key players contributing towards the global pruritus therapeutics market are Allergen, Bristol-Myers Squibb, Astellas Pharma, GlaxoSmithKline, Eli Lilly, Novartis, Merck, Sanofi, and Pfizer.

Get a sample of the report @

According to the World Health Organization (WHO), nearly 900 million people worldwide suffer from skin diseases at any given time, making them one of the most prevalent health issues globally. Atopic dermatitis, also known as atopic eczema, is a prominent skin disorder characterized by pruritus and has a prevalence rate of approximately 6.1-22.3% in Western countries. In the United States, an estimated 23-44 million people are likely to experience chronic pruritus in the context of both cutaneous and systemic conditions. The market for skin condition treatments is projected to reach USD 12.6 billion in terms of revenue, exhibiting a CAGR of 6.5% by 2027, driven by the rising incidence of skin conditions worldwide.

The prevalence of chronic pruritus significantly impacts individuals' daily functioning and quality of life. It can lead to mood disturbances, disrupted sleep patterns, increased anxiety, and depression. Consequently, pharmaceutical companies are actively developing novel drugs and treatments to help individuals suffering from chronic skin conditions. For example, Pfizer Inc., a leading global pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for EUCRISATM ointment 2% (crisaborole) in 2016. This innovative non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor is used for the treatment of mild to moderate atopic dermatitis.

The growing burden of skin diseases and the detrimental impact of pruritus on individuals' well-being have spurred the demand for effective therapeutic options. Continued research and development efforts are expected to drive advancements in pruritus treatments, providing relief and improving the quality of life for affected individuals.

To know more about the report @

Type (Revenue, USD Million; 2018-2028)

  • Corticosteroids
  • Antihistamines
  • Local Anesthetics
  • Counterirritants
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Disease Type (Revenue, USD Million; 2018-2028)

  • Skin conditions
  • Atopic Dermatitis
  • Allergic Contact Dermatitis
  • Urticaria
  • Others
  • Internal diseases
  • Nerve disorders
  • Psychiatric diseases
  • Irritation and allergic reactions

Treatment Type (Revenue, USD Million; 2018-2028)

  • Itchy skin treatment
  • Corticosteroid creams and ointments
  • Other creams and ointments
  • Oral medications

End-Use (Revenue, USD Million; 2018-2028)

  • Hospital 
  • Clinic
  • Others

Request a customization of the report @

Key Advantages of Pruritus Therapeutics Report:

  • Identification and analysis of the market size and competition
  • Qualitative and quantitative analysis of the market data
  • Data validated by industry experts after extensive primary and secondary research
  • Extensive regional analysis of the Pruritus Therapeutics industry
  • Profiling of key players along with their business overview,  business strategies, deals and partnerships, and product portfolio
  • SWOT and Porter’s Five Forces Analysis for in-depth understanding of the competitive landscape
  • Feasibility analysis and investment analysis to enable strategic investment decisions
  • Analysis of opportunities, drivers, restraints, challenges, risks, and limitations

Thank you for reading our report. For more details please connect with us and our team will ensure the report is customized to meet all the needs of clients. The report also offers a comprehensive regional analysis and specific countries can be included in the report according to the requirements.

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
Reports and Data | Web:
Check our upcoming research reports @
Visit our blog for more industry updates @